Insights
Search Results
Client Highlights
1.22.26
Wilson Sonsini Advises Janux Therapeutics on Patent Matters Related to License Agreement with Bristol Myers Squibb
On January 22, 2026, Janux Therapeutics (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), and Tumor Activated Immunomodulator (TRACIr) platforms, announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, the companies will develop a tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Wilson Sonsini Goodrich & Rosati advised Janux on patent matters related to the transaction.
Client Highlights
7.23.24
Wilson Sonsini Advises Vida Ventures on IP Matters Related to Third Arc Bio's $165 Million Series A Round
On July 23, 2024, Third Arc Bio Inc., a biotech company developing multifunctional antibodies optimized for T cell engagement across solid tumors and inflammatory & immunology (I&I) disease, announced a $165 million oversubscribed Series A financing that will advance the company through clinical studies to address significant unmet needs in oncology and autoimmunity. The company was launched in 2022 with seed financing from Omega Funds and has since advanced multiple programs that will enter the clinic starting in early 2025. The Series A investor syndicate was led by Vida Ventures and co-led by Cormorant Asset Management and Hillhouse Investment. Omega Funds continued their strong support of the company in the Series A and additional investors include Goldman Sachs Alternatives, BVF Partners LP, funds and accounts advised by T. Rowe Price Associates, Inc., Janus Henderson Investors, funds managed by abrdn Inc., Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, and AbbVie Ventures.
Client Highlights
3.20.24
Wilson Sonsini Advises Tempo Therapeutics on $12 Million Series A
On March 19, 2024, Tempo Therapeutics, a leading innovator in tissue engineering and regenerative medicine, announced the completion of a $12 million Series A equity financing round, led by Galaxy-Sirius Partners and Johnson & Johnson Innovation (JJDC). Wilson Sonsini Goodrich & Rosati has represented Tempo Therapeutics since its inception as a spinout from UCLA and currently represents the company on all legal matters.
Client Highlights
5.16.23
Firm Advises Boundless Bio on IP Matters Related to $100 Million Series C
On May 16, 2023, Boundless Bio, a clinical-stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, announced the closing of a $100 million Series C financing. The financing was co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors Sectoral Asset Management and Piper Heartland Healthcare Capital. Wilson Sonsini Goodrich & Rosati advised Boundless Bio on IP matters related to the transaction.
Client Highlights
4.17.23
Firm Advises on IP and Patent Matters for Merck’s $10.8 Billion Acquisition of Prometheus
On April 16, 2023, pharmaceutical company Merck announced the $10.8 billion acquisition of clinical-stage biotechnology company Prometheus in a deal that will boost Merck’s presence in immunology. Wilson Sonsini Goodrich & Rosati advised Prometheus on IP and patent matters related to the transaction.
Client Highlights
12.09.22
Wilson Sonsini Advises Prometheus Biosciences on IP Matters Related to $500 Million Offering
On December 8, 2022, Prometheus Biosciences, Inc. a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, announced the pricing of an underwritten offering of 4,545,455 shares of its common stock at a price to the public of $110 per share. All of the shares to be sold in the offering are to be sold by Prometheus. The gross proceeds to Prometheus from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $500 million. The offering is expected to close on or about December 13, 2022, subject to the satisfaction of customary closing conditions. In addition, Prometheus has granted the underwriters a 30-day option to purchase up to an additional 681,818 shares of common stock. Prometheus intends to use the net proceeds from this offering, together with its existing cash, cash equivalents, and short-term investments, to fund the development of PRA023, PRA052, and its other research and development programs and for working capital and general corporate purposes.
Client Highlights
4.28.21
Wilson Sonsini Advises Boundless Bio on IP Matters Related to $105 Million Series B
On April 28, 2021, Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, announced the closing of an oversubscribed $105 Million Series B financing. RA Capital Management and Nextech Invest co-led the financing, with participation from a top-tier syndicate of funds, including Fidelity Management & Research Company LLC, Redmile Group, Wellington Management, Surveyor Capital (a Citadel company), PFM Health Sciences, and Logos Capital. Current investors ARCH Venture Partners, City Hill Ventures, Vertex Ventures HC, GT Healthcare Capital Partners, Boxer Capital of Tavistock Group, and Alexandria Venture Investments also participated in the Series B. With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ecDNA Harboring Oncogenes (ECHO™) companion diagnostic and expand its pipeline of novel cancer therapies targeting ecDNA.
Client Highlights
3.15.21
Firm Advises Prometheus Biosciences on IP Matters Related to Initial Public Offering
On March 11, 2021, Prometheus Biosciences, a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease, announced the pricing of its upsized initial public offering of 10,000,000 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by Prometheus. The shares began trading on the Nasdaq Global Select Market on March 12 under the ticker symbol “RXDX.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prometheus, are expected to be $190 million. Wilson Sonsini Goodrich & Rosati is advising Prometheus on intellectual property matters related to the transaction.
The offering is expected to close on March 16, subject to the satisfaction of customary closing conditions. In addition, Prometheus has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. SVP Leerink, Credit Suisse, Stifel, and Guggenheim Securities are acting as joint bookrunning managers for the offering.
The Wilson Sonsini team advising Prometheus on intellectual property matters related to the offering includes Sara Pennebaker, Alicia Umpierre, Erin Boyle Anderson, Morgan Brown, Jacob Panangat, Brian Brown, Farah Gerdes, and Matthew Bresnahan.
For more information, please see Prometheus Biosciences’ press release.
The offering is expected to close on March 16, subject to the satisfaction of customary closing conditions. In addition, Prometheus has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. SVP Leerink, Credit Suisse, Stifel, and Guggenheim Securities are acting as joint bookrunning managers for the offering.
The Wilson Sonsini team advising Prometheus on intellectual property matters related to the offering includes Sara Pennebaker, Alicia Umpierre, Erin Boyle Anderson, Morgan Brown, Jacob Panangat, Brian Brown, Farah Gerdes, and Matthew Bresnahan.
For more information, please see Prometheus Biosciences’ press release.
Client Highlights
12.16.20
Wilson Sonsini Advises Atsena on Patent Matters Related to Series A Financing
On December 16, 2020, Atsena Therapeutics, a clinical-stage gene therapy company developing novel treatments for inherited forms of blindness, announced it has closed an oversubscribed $55 million Series A financing. Wilson Sonsini Goodrich & Rosati advised Atsena Therapeutics on the intellectual property matters related to the financing.
Client Highlights
9.30.20
Wilson Sonsini Advises LifeSci Acquisition Corp. on IP Matters Related to Acquisition of Vincera Pharma
On September 29, 2020, LifeSci Acquisition Corp. (LSAC), a blank check company targeting the biopharma, medical technology, digital health, and healthcare services sectors and Vincera Pharma, Inc., a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, announced that they have entered into a definitive agreement for a business combination.